Drugs / FONADELPAR
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT02929823 | Sep 2016 → May 2017 | corneal disorder | Senju Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02104388 | Apr 2014 → Aug 2015 | corneal disorder | Senju Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03527212 | Aug 2018 → Mar 2019 | dry eye syndrome | Senju Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FONADELPAR | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545186 ↗ |
| Known as | NPS-005 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545186 ↗ |
| Known as | SJP-0035 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03527212 ↗ |
| Known as | SJP-0035 ophthalmic solution | “This Phase 2a study (Study SJP-0035/2-02) is being conducted to evaluate the safety and efficacy of 2 doses of SJP-0035 ophthalmic solution in patients with corneal epithelial...” NCT02929823 ↗ |
| Action | Activate | “Peroxisome proliferator-activated receptor delta agonist” CHEMBL3545186 ↗ |
| Modality | Small molecule | — CHEMBL3545186 ↗ |
| Target | PPARD | “Peroxisome proliferator-activated receptor delta agonist” CHEMBL3545186 ↗ |